| Identification | Back Directory | [Name]
m-tolyl 5-chloro-2-(ethylsulfonyl)pyrimidine-4-carboxylate | [CAS]
882366-16-7 | [Synonyms]
SBI115
SBI-115
SBI 115
SBI-115; SBI 115; SBI115
m-tolyl 5-chloro-2-(ethylsulfonyl)pyrimidine-4-carboxylate
3-Methylphenyl 5-chloro-2-(ethylsulfonyl)-4-pyrimidinecarboxylate
4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester | [Molecular Formula]
C14H13ClN2O4S | [MDL Number]
MFCD07537427 | [MOL File]
882366-16-7.mol | [Molecular Weight]
340.78 |
| Chemical Properties | Back Directory | [Boiling point ]
529.7±60.0 °C(Predicted) | [density ]
1.386±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO:109.0(Max Conc. mg/mL);319.86(Max Conc. mM) | [form ]
Solid | [pka]
-7.73±0.49(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5[1]. | [References]
[1] Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218. DOI:10.1002/hep.29284 |
|
|